# To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

> **NCT07303465** · PHASE2 · RECRUITING · sponsor: **Ranok Therapeutics (Hangzhou) Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- KRAS G12D Mutations
- Pancreatic Ductal Adenocarcinoma (PDAC)

## Interventions

- **DRUG:** RNK08954

## Key facts

- **NCT ID:** NCT07303465
- **Lead sponsor:** Ranok Therapeutics (Hangzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-14
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07303465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07303465, "To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07303465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*